Compare Eli Lilly And Co (LLY) vs Taiwan Semiconductor Mfg. Co. Ltd. (TSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Taiwan Semiconductor Mfg. Co. Ltd. — how do they compare? Eli Lilly And Co trades at $1,160.05 (market cap $1.02T), while Taiwan Semiconductor Mfg. Co. Ltd. trades at $417.85 (market cap $1.88T). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is the larger of the two by market cap, and Taiwan Semiconductor Mfg. Co. Ltd. pays the higher dividend (0.94%). Which is the better fit depends on your goals.
| LLY | TSM | |
|---|---|---|
Market Cap | $1.02T | $1.88T |
Sector | Health | Technology |
52-Week High | $1.24K | $477.57 |
52-Week Low | $625.65 | $227.33 |
Enterprise Value | $1.06T | $1.81T |
Dividend Yield | 0.6% | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
TSM is trading at $401.43, up 0.77% today, amid a bearish technical signal but strong fundamental performance. The company reported robust Q2 2026 earnings, beating estimates with 33.7% revenue growth, and announced a $100 billion expansion in Arizona to capitalize on AI chip demand. Valuation ratios like a P/E of 29.81 and P/S of 14.88 reflect premium pricing, while profitability remains high with a net margin of 49.92%.
The outlook is positive due to sustained AI-driven demand and strategic investments, but risks include sector volatility and execution challenges in expansion. Analyst consensus is strongly bullish with a $547.50 price target, suggesting significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Taiwan Semiconductor Mfg. Co. Ltd.
Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.
Read more on TSM →
